Atara Biotherapeutics (NASDAQ:ATRA) Stock Price Crosses Below 50 Day Moving Average of $0.73

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.73 and traded as low as $0.68. Atara Biotherapeutics shares last traded at $0.71, with a volume of 832,144 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, April 5th.

Atara Biotherapeutics Stock Performance

The business’s fifty day moving average is $0.72 and its 200-day moving average is $0.80. The firm has a market cap of $78.90 million, a P/E ratio of -0.25 and a beta of 0.69.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.05. Atara Biotherapeutics had a negative net margin of 3,220.88% and a negative return on equity of 783.31%. The firm had revenue of $4.25 million during the quarter, compared to the consensus estimate of $2.45 million. Analysts predict that Atara Biotherapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ATRA. Vanguard Group Inc. grew its holdings in Atara Biotherapeutics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 6,686,043 shares of the biotechnology company’s stock worth $3,429,000 after acquiring an additional 80,110 shares during the period. GSA Capital Partners LLP bought a new stake in Atara Biotherapeutics during the 4th quarter valued at $402,000. Barclays PLC raised its holdings in Atara Biotherapeutics by 693.9% during the fourth quarter. Barclays PLC now owns 132,847 shares of the biotechnology company’s stock worth $69,000 after buying an additional 116,114 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Atara Biotherapeutics by 5.8% in the fourth quarter. Northern Trust Corp now owns 845,427 shares of the biotechnology company’s stock valued at $434,000 after buying an additional 46,505 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Atara Biotherapeutics by 6,214.1% during the fourth quarter. UBS Group AG now owns 3,693,225 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 3,634,733 shares during the last quarter. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.